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Abstract: The clinical presentation of Human African Trypanosomiasis (HAT) due to Trypanosoma
brucei gambiense is well known, but knowledge on long-term sequelae is limited. In the frame of
studies conducted between 2004 and 2005 in the Democratic Republic of the Congo (DRC), the
prevalence of HAT related signs and symptoms were evaluated before the start of treatment and
at the end of treatment. To explore possible long-term sequelae, the same clinical parameters were
assessed in 2017 in 51 first stage and 18 second stage HAT patients. Signs and symptoms 12–13 years
after treatment were compared to before and immediately after treatment and to controls matched
for sex and age (±5 years). In first stage HAT patients, the prevalence of all signs and symptoms
decreased compared to before treatment but were still higher after 12–13 years than immediately at
the end of treatment and in the control group. In second stage HAT patients, all HAT-specific findings
had continuously decreased to the point where they were in the range of the healthy control group.
In a selection of oligosymptomatic first stage HAT patients, no trypanosomes were detected in the
blood by microscopic examination or PCR. An oligosymptomatic presentation of HAT due to the
persistence of parasites in compartments, where first stage HAT medications do not penetrate, could
not be ruled out.
Keywords: human African trypanosomiasis; sequelae; serology; treatment; oligosymptomatic HAT
1. Introduction
Human African trypanosomiasis (HAT) is caused by the protozoan parasites Trypanosoma brucei
gambiense (T.b. gambiense) and Trypanosoma brucei rhodesiense (T.b. rhodesiense), which are transmitted by
tsetse flies. Whereas the T.b. gambiense form is characterized by a progressive course typically lasting
three years [1], the T.b. rhodesiense form is usually acute, and death occurs within weeks or months
of infection.
T.b. gambiense is endemic in foci in Western and Central Africa and today causes more than 98% of
reported cases of HAT. The disease occurs in two stages, the first, or hemolymphatic, stage without
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invasion of the central nervous system (CNS) and the second, or neurological, stage with invasion of
the CNS by the trypanosomes.
According to the last WHO report (WHO interim guidelines for treatment of gambiense human
African trypanosomiasis, August 2019) [2], the worldwide number of T.b. gambiense HAT cases dropped
from over 25,000 in the year 2000 to below 1000 reported cases worldwide in 2018 [2].
Fever, headache, pruritus, lymphadenopathy, and, to a lesser extent, hepato-splenomegaly are the
leading signs and symptoms of the first stage but may also be present, to a lesser degree, in the second
stage. During the second stage, neuro-psychiatric disorders such as lethargy, aggressive behaviour,
logorrhoea, psychotic reactions, mood changes, and sleep disturbances/disorders dominate the clinical
presentation. The neurological symptoms include tremor, general motor weakness, paralysis of an
extremity, epilepsy, akinesia, and abnormal movements (dyskinesia, unspecific movement disorders,
Parkinson-like movements, speech disorders) [3–8]. Sleep disorder with somnolence and short
interposed sleeping episodes during the day and at night are imposing clinical symptoms from which
“sleeping sickness” derives its name. Total sleep duration, however, remains normal [9].
HAT had always been perceived and described as inevitably fatal if untreated. However,
oligosymptomatic forms of HAT with few symptoms, non-detectible parasites, and persistent serological
titers were recently described along with their potential role for transmission of HAT [10,11]. The
clinical presentation of T.b. gambiense HAT has been well documented, but studies on long-term
sequelae of HAT have not been performed. The present observational case control study describes the
clinical signs and symptoms of HAT patients before treatment and 12–13 years after.
2. Materials and Methods
2.1. Study Design and Setting (See also Flowcharts below)
The present study assessed the prevalence of HAT related long-term clinical sequelae (signs and
symptoms 12–13 years after treatment) and compared signs and symptoms of the HAT patients before,
immediately after, and 12–13 years after treatment. Patients at follow-up time were also compared
with controls matched by sex and age (±5 years).
This follow-up study was conducted in two phases from 19 July to 14 September 2017 and from
3 May to 30 May 2019 at the Hôpital Evangélique de Vanga, located in the Kwilu province of the
Democratic Republic of the Congo (DRC). The area is rural; villages are very remote and only accessible
with major efforts by very difficult roads.
2.2. Participants
In a clinical study carried out in 2004 on endocrinological changes and the involvement of the
heart in second stage HAT (detection of parasite, pathological cerebrospinal fluid), clinical parameters
from 29 patients were assessed before treatment, at the end of treatment, and after a follow-up of three
months [12–14]. Additionally, in the framework of clinical trials carried out between 2004 and 2005,
clinical parameters were documented before and after treatment (but without a follow-up of three
months) in 96 first stage HAT patients (parasitology confirmed) in Vanga. In these trials, the safety and
efficacy of the newly developed drug pafuramidine was compared to the standard treatment with
pentamidine for first stage HAT [15,16].
A list of all formerly recruited patients in the above-mentioned studies was compiled, and their
place of residence (village) was traced. The villages for the recruitment of study participants were
chosen according to the number of eligible patients living there and the accessibility of the villages
(distance to Vanga hospital, navigability of roads, and distance between affected villages). According
to these parameters, visits were planned, starting with a visit that allowed the enrollment of the largest
possible number of patients. Accessible persons were included in the study after informed consent
with the exception of patients with one of the following exclusion criteria: history of severe chronic
diseases such as tuberculosis, HIV, cancer, liver cirrhosis, and diabetes mellitus. In patients who died
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or were not accessible, a third-party history by a family member or friend was taken. These patients
were not included in the analysis but were discussed separately.
2.3. Sample Size
Different clinical parameters of HAT have largely different frequencies. The calculation of a sample
size yielding 80% power (α = 0.05) was, e.g., 11 patients for sleeping disorders versus 485 patients
for abnormal behavior. It was therefore decided to aim at a minimum 60 patients, which would be
sufficient to allow the covering of the major signs and symptoms. Due to the limited number of
available patients, the sample size calculation was only performed for the first stage HAT patients.
Ninety-six first stage and 29 second stage patients who participated in the former studies lived in the
perimeter of the Vanga hospital.
2.4. Study Procedure/Clinical Examination
The study was conducted in two parts—a site visit to the villages as described above, followed
by a laboratory assessment at the hospital for the first stage HAT patients with clinical signs and
symptoms (see below). The original working hypothesis was that no or only rare sequelae or signs
of continued infection would be found in treated HAT patients revisited more than 10 years after
treatment. Therefore, the study focused on clinical signs and symptoms of HAT patients 12–13 years
after treatment. The second part of the study emerged from the findings, which had revealed a
significant number of first stage HAT patients with continued or returning complaints. The resulting
follow-up study, comprising blood examinations, could only be done with about two years of delay, due
to the necessary protocol amendment, time-consuming ethical clearance, and challenges of accessibility
and free movement in the election period in the DRC.
For each former patient (=a case), a control person matched by age (±5 years) and sex was enrolled.
Family members were preferred and, if not available, hospital personnel or patients with minor surgical
problems (i.e., herniotomy) were enrolled instead.
In all HAT patients and controls, a short history and physical examination was established.
Questions regarding the symptoms of HAT were asked in the same manner as in the former original
study and trials, and the case report form used to compare signs and symptoms was based on those
used in the previous trials. The data collected were compared to those before treatment and after
treatment from the former studies.
2.5. Additional Blood Examination on Patients with Symptoms
For the second part of the study, 15 first stage HAT patients who were still oligosymptomatic
and had shown clinical signs or symptoms such as headache, sleep disorders, pruritus, or minor
neurological problems during the village visits were invited to report to the hospital for additional
tests. The following laboratory tests were performed: Microscopic examination of the blood and the
aspiration fluid of enlarged lymphatic glands (if present) for the presence of trypanosomes, serologic
testing for trypanosomiasis (CATT/T.b.gambiense, Institute of Tropical Medicine, Antwerp, Belgium;IFA,
in-house test, Swiss Tropical and Public Health Institute, Basel, Switzerland), and PCR from blood
samples. CATT was performed immediately after blood withdrawal in the DRC, and EDTA-blood and
serum samples for IFA and PCR were stored in aliquots at −20 ◦C at the study site until transfer on dry
ice to Switzerland.
2.6. T.b. gambiense Card Agglutination Test for Trypanosomiasis (CATT)
The CATT is a direct agglutination test using lyophilized bloodstream forms of T.b. gambiense
variable antigen type LiTat 1.3. It detects specific antibodies in the blood, serum, or plasma of patients
infected with T.b. gambiense [17]. The test was performed according to the kit manual. For each
participant, one CATT test was performed on undiluted whole blood.
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The CATT exhibits a sensitivity of 87%–98% [17,18] and a specificity of 95.9% on undiluted
whole blood. Cross reactivity with antibodies generated against Plasmodium spp. and other parasites
is possible.
2.7. Trypanosoma brucei IFA, Malaria IFA, and Leishmania IFA Serological Tests
Immunofluorescence staining was performed with bloodstream forms of T.b. brucei (strain STIB
345) in addition with Plasmodium falciparum (strain NF54) or liver sections of Leishmania donovani (strain
MHOM-ET-67/L82) infected hamster mounted on glass slides. Slides were stored at −80 ◦C until day of
use. For IFA analysis, slides were quickly air-dried at room temperature and fixed with acetone. Sera
were diluted in PBS pH 7.2 and applied to the slide-slots. Three control sera were present on each slide;
one positive, one equivocal, and one negative control. After 25 min of incubation at 37 ◦C in a wet
chamber, slides were washed with PBS pH 7.2 and air-dried. FITC conjugated F(ab)’2 anti-IgG/A/M
(BioRad, #30244) diluted in 0.01% Evans blue in PBS was added, slides were incubated for 25 min at
37 ◦C, washed, dried, and a cover glass was mounted with buffered glycerol. Slides were examined
immediately with a fluorescence microscope. The serodiagnostic test exhibits a sensitivity of 98% for
infections with T.b. rhodesiense or T.b. gambiense and a specificity of >99% for serum samples from
healthy blood donors. The IFA exhibits a sensitivity of >99% for Plasmodium spp. and a specificity of
98% for healthy blood donor samples. The test has a sensitivity of >96% for visceral leishmaniasis and
a specificity of >99% for heathy blood donor sera. Cross reactivity between the mentioned parasites
antigens is possible.
2.8. Plasmodium falciparum spp. ELISA
Malaria serology was performed with an in-house screening ELISA for detection of specific
Plasmodium spp. antibodies. P. falciparum antigen (strain NF54) was coated in 0.05 M sodium carbonate
buffer, pH 9.6, to Immulon 2HB plates (, Thermo Scientific, Wohlen, Switzerland,). After washing,
diluted sera were added to the plates and incubated for 15 min at 37 ◦C. After additional washing steps,
horseradish peroxidase conjugated goat-anti-human-IgG (KPL, 474-1006, BioConcept Ltd, Allschwil,
Switzerland) was added. Plates were incubated for 15 min at 37 ◦C, subsequently washed, and
o-Phenylendiamine Dihydrochloride (OPD, Sigma, Buchs, Switzerland) was added. Reaction was
stopped with 8 M H2SO4, and absorption was read with a Multiscan FC reader (ThermoScientific,
Wohlen, Switzerland) at 492 nm. All sera giving positive or equivocal results were additionally tested
with an in-house confirmatory Malaria IFA.
2.9. Real-Time PCR
For molecular analysis, 5 mL of whole blood samples were lysed and stored at the hospital
site by adding an equal volume of guanidine-HCl 6 M with 0.1 M EDTA pH = 8, according to
previous publications [19,20]. These samples were kept at 4 ◦C until shipment to Switzerland.
Upon arrival, samples were immediately processed. For this, samples were heated at 100 ◦C for
15 min, and 500 µL of the guanidine-HCl-EDTA whole blood was used for extraction using the
QIAamp DNA Mini Kit from Qiagen (Hilden, Germany), according to the manufacturer’s instructions.
DNA was eluted in 100 µL AE buffer (provided by the kit). The PCR targets the 18S rRNA gene
of the Trypanozoon spp. (including the detection of T.b. brucei, T.b. gambiense, T.b. rhodesiense,
T. evansi, and T. equiperdum) as previously described for a conventional PCR format [21]. Primer
and probe sequences were newly designed and adapted to the real-time PCR format (forward
primer: 5′-TAGTTTTGTGCCGTGCCAGT-3′, reverse primer: 5′-CGCTCCCGTGTTTCTTGTATC-3′,
and TaqMan probe: 5′-FAM-TCGGACGTG-iQ500-TTTTGACCCACGC-BHQ1-3′), resulting in an
amplicon of 97 basepairs. The PCR reaction mixture contained 5 µL DNA, 1x GoTaq Probe Master
Mix from Promega (Madison, USA), 800 nmol forward and reverse primer, and 200 nmol probe in
a total reaction volume of 25 µL. The PCR program started with a step at 50 ◦C for 2 min and 95 ◦C
for 10 min, followed by 45 cycles of 95 ◦C for 15 s and 58 ◦C for 1 min. Plasmid containing the
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97 bp amplicon sequence, as well as adjacent base pairs, was used as a positive control. The assay
was optimised on T.b. gambiense and T.b. rhodesiense culture samples and spiked blood samples.
Analytical sensitivity of the assay was 1 plasmid copy/µL DNA, and 5–50 parasites/mL spiked
whole blood. Specificity was tested against DNA samples from Babesia divergensis, Cryptosporidium
spp., Cyclospora cayetanensis, Leishmania aethiopica, L. braziliensis, L. donovani, L. infantum, L. mexicana,
Neospora caninum, Plasmodium falciparum, P. vivax, P. knowlesi, P. malariae, P. ovale, Sarcoycstis hominis,
Toxoplasma gondii, and Trypanosoma cruzi, and were found to be 100%.
2.10. Statistical Analysis
Categorical characteristics were summarized as counts and proportions, continuous characteristics
as means, standard deviations, medians, and interquartile ranges. Paired comparisons were tested
using McNemars’ exact test or the Wilcoxon signed rank test depending on the nature of the compared
factors. SAS version 9.4 (2002–2012, SAS Institute, Cary, NC, USA) was used to perform the statistical
analysis. The level of significance was set to an alpha level <0.05.
2.11. Ethics Statement
The study protocol was approved by Ethikkommission Nordwest-und Zentralschweiz (EKNZ)
(2017-00471; 12.4.2017) and Comité d’Éthique de l’Université Protestante au Congo (UPC) (CEUPC)
(0044; 13.6.2017). Prior to enrolment, all participants gave informed written consent.
3. Results
In the region of Vanga, 96 first stage and 29 second stage HAT patients were recruited into several
studies and trials between 2004 and 2005 [12–16]. The recruitment of participants for the present study
took place during three visits to the following villages: (i) Kikongo Tango-Milundu, (ii) Nsalu, and
(iii) Mayoko-Nkai.
The flowchart of the study, including the number of participants, is shown in Figure 1.
In 69 out of 92 (75%) of the eligible patients, a history and clinical examination could be performed.
Fifty-one were previous first stage and 18 were previous second stage HAT patients. Ten out of 92
(11%) were not accessible but, according to oral communication by relatives or friends, were all in good
health without any long-term sequelae of HAT. Five out of 92 (5%) died, two of them in the peripartum
period of causes unrelated to HAT, and three without a clear diagnosis. Of these three patients, one
died due to malnutrition, probably unrelated to HAT, one due to an undefined disease with unspecified
swelling but without fever, and the third one due to unknown causes one month after HAT treatment.
No information was available for eight out of 92 (9%) of the former patients. There was no history of
a confirmed relapse for any of the patients followed up in this study. During the village visits, only
clinical investigations, but no specific HAT diagnostic tests, were performed. At this point, no patient
was suspected to have HAT; therefore, no blood tests had been planned for this phase of the study.
Table 1 shows the characteristics for patients with previously first (n = 51) and second (n = 18)
stage HAT and their matched controls. Tables 2 and 3 show the prevalence of signs and symptoms
before treatment and at the long-term follow-up, for first and second stage HAT, respectively. Figures 2
and 3 show the development of these signs and symptoms at the different examined time points.
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Table 1. Descriptive characteristics for first a d second stage HAT patients and their contr ls.
Char cteristic
First Stage HAT Second Stage HAT
Patients
(n = 51)
Controls
(n = 51)
Patients
(n = 18)
Controls
(n = 18)
Age * (years):
Mean ± SD 43.9 ± 12.5 42.7 ± 12.5 52.0 ± 15.8 50.9 ± 14.5
Median (IQR) 41 (35 to 50) 42 (32 to 51) 47.5 (37 to 64) 48 (36 to 64)
Gender: n (%)
Male 14 (27.5) 14 (27.5) 9 (50.0) 9 (50.0)
Female 37 (72.5) 37 (72.5) 9 (50.0) 9 (50.0)
* Age of controls matched within ±5 years of age of patients; SD = standard deviation; IQR = interquartile range
(first to third quartile).
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Table 2. First stage HAT: Signs and symptoms for patients before treatment and at 12 year follow-up and for their controls.
Symptom/Sign Level
Before Treatment 12 Year Follow-up p-Value * Controls
†
p-Value *,§
n (%) n (%) n (%)
Lymphadenopathy Absent 1 (2.0) 48 (94.1) <0.0001 49 (96.1) 0.6547
Palpable 50 (98.0) 3 (5.9) 2 (3.9)
Headache
Absent 13 (26.0) 35 (70.0) <0.0001 43 (86.0) 0.0325
Present/Unbearable 37 (74.0) 15 (4) (30.0) 7 (14.0)
Pruritus
Absent 37 (72.6) 45 (88.2) 0.0005 50 (98.0) 0.0588
Present/Visible traces of scratching 14 (27.4) 6 (4) (11.8) 1 (2.0)
Daytime sleep Normal 51 (100.0) 49 (96.1) - 51 (100.0) -
Repeatedly/Continuously 0 (0.0) 2 (2) (3.9) 0 (0.0)
Nighttime sleep Normal 51 (100.0) 47 (92.2) - 51 (100.0) -
Few hours/Rare 0 (0.0) 4 (4) (7.8) 0 (0.0)
Tremor
Absent 51 (100.0) 48 (94.1) - 51 (100.0) -
Visible/Severe 0 (0.0) 3 (3) (5.9) 0 (0.0)
Speech impairment Absent 51 (100.0) 50 (98.0) - 51 (100.0) -
Present/Non-interpretable 0 (0.0) 1 (1) (2.0) 0 (0.0)
Abnormal movement Absent 51 (100.0) 51 (100.0) - - -
Walking disability Absent 51 (100.0) 51 (100.0) - - -
General motor weakness Absent 51 (100.0) 51 (100.0) - - -
Unusual behavior Absent 51 (100.0) 51 (100.0) - - -
Inactivity Absent 51 (100.0) 51 (100.0) - - -
Aggression Absent 51 (100.0) 51 (100.0) - - -
Disturbed appetite Normal 51 (100.0) 51 (100.0) - - -
* McNemar’s exact test; † Each patient was matched to a control by sex and age (±5 years); § For patients at 12 year follow-up and their healthy controls; (x) Number of new onsets.
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Table 3. Second stage HAT: Signs and symptoms for patients before treatment and at 12 year follow-up and for their controls.
Symptom/Sign Level
Before Treatment 12 Year Follow-Up p-Value * Controls
†
p-Value *,§
n (%) n (%) n (%)
Lymphadenopathy Absent 1 (5.6) 17(94.4) 0.0020 17 (100.0) -
Palpable 17 (94.4) 1 (5.6) 0 (0.0)
Headache
Absent 8 (44.4) 16 (88.9) 0.0156 17 (94.4) 0.5637
Present/Unbearable 10 (55.6) 2 (1) (11.1) 1 (5.6)
Pruritus
Absent 9 (50.0) 18 (100.0) - 18 (100.0) -
Present/Visible traces of scratching 9 (50.0) 0 (0.0) 0 (0.0)
Daytime sleep Normal 12 (66.7) 18 (100.0) - 18 (100.0) -
Repeatedly/Continuously 6 (33.3) 0 (0.0) 0 (0.0)
Nighttime sleep Normal 10 (55.6) 18 (100.0) - 18 (100.0) -
Few hours/Rare 8 (44.4) 0 (0.0) 0 (0.0)
Tremor
Absent 13 (72.2) 18 (100.0) - 18 (100.0) -
Visible/Severe 5 (27.8) 0 (0.0) 0 (0.0)
Speech impairment Absent 16 (88.9) 18 (100.0) - 18 (100.0) -
Present/Non-interpretable 2 (11.1) 0 (0.0) 0 (0.0) -
Abnormal movement Absent 18 (100.0) 18 (100.0) - 18 (100.0) -
Walking disability Absent 13 (72.2) 18 (100.0) - 18 (100.0) -
Present/Walking with help/inability to walk 5 (27.8) 0 (0.0) - 0 (0.0)
General motor weakness
Absent 14 (77.8) 18 (100.0) - 18 (100.0) -
Ability to stand from chair no hands/No
ability to stand 4 (22.0) 0 (0.0) - 0 (0.0)
Unusual behavior
Absent 14 (77.8) 18 (100.0) - 18 (100.0) -
Visible/Severe 4 (22.0) 0 (0.0) - 0 (0.0)
Inactivity Absent 11 (61.1) 18 (100.0) - 18 (100.0) -
Reduced workforce/Inability to perform
daily tasks 7 (38.9) 0 (0.0) - 0 (0.0)
Aggression Absent 12 (66.7) 18 (100.0) - 18 (100.0) -
Sporadic/Severe, requires observation 6 (33.3) 0 (0.0) - 0 (0.0)
Disturbed appetite
Normal 16 (88.9) 18 (100.0) - 18 (100.0) -
Disturbed/Severely 2 (11.1) 0 (0.0) - 0 (0.0)
* McNemar’s exact test; † Each patient was matched to a control by sex and age (±5 years); § For patients at 12 year follow-up and their healthy controls; (x) Number of new onsets.
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3.1. Lymphadenopathy
Lymphadenopathy was the most frequently observed sign before treatment in first stage (98%)
and second stage (94.4%) HAT patients. Twelve years after treatment, it was detected only in 5.9% first
and in 5.6% second stage patients, which was comparable to the control groups (3.9% and 0%).
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3.2. Headache
Headache was the most frequent complaint of HAT patients before treatment and was more
frequent in the first stage (74%, including 2% with unbearable headache) than in the second stage
(55.6%). In first stage HAT, headaches decreased to 6% at the end of treatment but increased thereafter
to 30% (none with unbearable headache) 13 years later, which is significantly higher than in the
control group (14%). One patient asked for further examination pertaining to the headache, which
revealed the cause of the headache to be posttraumatic after a head injury without association to HAT.
In second stage HAT, headaches decreased to 11% 12–13 years after treatment, compared to 5.6% in the
control group.
3.3. Pruritus
Pruritus was the second most frequent complaint of HAT patients and was less frequent in the
first stage (27.4%, including 6% with scratching marks) than in the second stage (50%) before treatment.
It decreased to 4% after treatment and re-increased to 11.8% at the 12 year follow-up (none with
scratching marks) in first stage and decreased to none in second stage HAT, comparable to the control
group (2%).
3.4. Sleep Disorder
In first stage HAT, sleep disorders were neither observed before nor after treatment, but 3.9%
reported daytime sleep and 7.8% reported sleep disorders during the night 12–13 years later. In second
stage HAT, daytime sleep decreased from 33% and night time sleep disorders from 44% before treatment
stepwise to none 12 years after treatment, equal to the healthy control group.
3.5. Neurological Disorders
In first stage HAT, neurological disorders were not described, before or after treatment, but
tremor was reported in 6% and speech disorders in 3% at follow-up. In the second stage, neurological
disorders such as speech impairment (11%), walking disability (28%), motor weakness (22%), and
unusual behavior (22%) were observed before treatment, decreasing continuously post treatment, and
had disappeared completely after 12–13 years.
3.6. Blood Analysis4
Blood analysis was performed only in the second phase of the study for symptomatic follow-up
patients from the group with previous first stage HAT. Trypanosomes could not be detected in any of
these 15 patients, neither by direct blood examination nor by real time PCR. The CATT was negative for
all patients, but IFA using T. b. brucei antigen was positive in most patients (see Table 4). None of the
15 patients showed a positive Leishmania serology. By contrast, all patients exhibited a positive malaria
serology in ELISA and IFA, which can be explained by the region being an endemic area for malaria.
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Table 4. Real-time PCR, CATT, T. brucei, Malaria, and Leishmania serology of 15 follow-up patients.
Real-time PCR
Trypanosoma
CATT
Test T. Brucei Serology Malaria Serology Leishmania Serology
Serum Result Result IFA(Titre) Result
ELISA
(OD)
IFA
(Titre) Result
IFA
(Titre) Result
P07 negative negative 1/320 positive 1.59 1/1280 positive <1/80 negative
P14 negative negative 1/160 equivocal 1.00 1/1280 positive <1/80 negative
P28 negative negative 1/640 positive 1.84 1/1280 positive <1/80 negative
P29 negative negative <1/160 negative 1.62 1/1280 positive <1/80 negative
P42 negative negative 1/320 positive 1.95 1/1280 positive <1/80 negative
P50 negative negative 1/320 positive 1.82 1/1280 positive <1/80 negative
P51 negative negative 1/640 positive 1.76 1/1280 positive <1/80 negative
P53 negative negative 1/320 positive 1.65 1/1280 positive <1/80 negative
P55 negative negative 1/640 positive 1.71 1/1280 positive <1/80 negative
P56 negative negative 1/320 positive 1.73 1/1280 positive <1/80 negative
P57 negative negative 1/320 positive 1.30 1/640 positive <1/80 negative
P58 negative negative 1/640 positive 1.26 1/1280 positive <1/80 negative
P62 negative negative 1/320 positive 1.74 1/1280 positive <1/80 negative
P63 negative negative 1/160 equivocal 1.74 1/1280 positive <1/80 negative
P64 negative negative 1/320 positive 2.09 1/1280 positive <1/80 negative
Cutoffs, T. brucei IFA: <1/160 negative, 1/160 equivocal, ≥1/320 positive; Malaria ELISA: <0.15 negative, 0.15–0.29
equivocal,≥0.30 positive; Malaria IFA: <1/40 negative, 1/40 equivocal,≥1/80 positive; Leishmania IFA: <1/80 negative,
1/80 equivocal, ≥1/160 positive.
4. Discussion
To the best of our knowledge, this is the first study assessing the long-term sequelae of first and
second stage HAT patients more than 10 years after initial treatment, comparing them to healthy controls.
The study evaluated the clinical signs and symptoms before treatment, immediately after treatment,
and 12–13 years after treatment in 51 first stage and 18 second stage HAT patients. A surprisingly high
percentage (75%) of the eligible and accessible patients could be enrolled in the present study, while
information on the health condition (including death) of 15% of the patients could be gathered from
relatives and friends. In only 10% of the eligible patients was no information available.
Five cases were lost to follow-up because of death. In two of these, HAT could be ruled out as the
cause of death, and in the other three, HAT was unlikely as the cause of death according to information
from friends and relatives.
In first stage HAT patients, the prevalence of all signs and symptoms (except lymphadenopathy)
had decreased 12–13 years after treatment compared to before treatment, but was still higher than
immediately after the end of treatment and in the control group. The high prevalence of headaches
(31%), pruritus (12%), and even the presence of neuropsychiatric symptoms such as tremor (6%),
speech impairment (2%), and sleeping problems (12%) is worrying. All patients with neuropsychiatric
symptoms also suffered from headaches. No relapse was clinically suspected in any of the patients or
reported by the patients in the time before the long-term follow-up.
In second stage HAT patients treated with melarsoprol, all HAT specific signs and symptoms
decreased steadily at the examined time-points towards a range of the healthy control group 12–13 years
post-treatment. Only headache was reported in 11%, but this was not significantly different compared
to the control group.
The higher prevalence of symptoms in first stage than in second stage HAT patients at follow-up
is surprising and contradictory to former studies. In children treated with melarsoprol, signs
and symptoms one month to four years after treatment were more frequently reported in second
stage patients (22 symptoms in 28 patients) than in their first stage counterparts (25 symptoms in
92 patients) [22]. In contrast to our results, neither headache nor pruritus were the main symptoms,
but were primarily neuropsychiatric symptoms: mental confusion (7.5%), changes in character (11.5%),
memory problems (11.5%), language problem (3%), and sleeping disorders (5%). Furthermore, changes
in growth in young participants, 6–20 years of age, formerly treated for HAT, were more accentuated
Trop. Med. Infect. Dis. 2020, 5, 10 12 of 15
in second stage HAT compared to first stage HAT [23]. The subjects treated for first and second stage
HAT had a smaller body weight (−4.25 kg), were 3 cm shorter, and had a smaller mid-upper-arm
circumference (−1.15 cm) than the control group matched for age, sex and residence. These changes
were more accentuated in second stage than in first stage patients: body weight from −4.9 to −2.6 kg,
height from −4.9 to −2 cm, and mid-upper-arm circumference from −2 to −1 cm [23]. Differences to
these studies could eventually be explained by a relatively low number of patients and a different
study design (i.e., age of patients, different follow-up period, different context).
In first stage HAT patients, the clear improvement of the signs and symptoms after treatment
was expected, but the reappearance of such symptoms 12–13 years post-treatment is surprising. In a
follow-up examination of the patients, no trypanosomes could be detected in any of them, neither
by direct microscopic examination nor by real time PCR of the blood. The CATT was negative for
all 15 former first stage HAT patients with persistent symptoms, but 80% of them were positive in
the Trypanosoma serology by IFA. In addition, 13% of the 15 participants showed an equivocal result
in IFA, and only 7% were negative. The positive Trypanosoma serology by IFA could be explained
by either long term-persisting anti-trypanosomal antibodies, a boost of immunity without an actual
measurable infection due to repetitive infected tsetse bites [24], the presence of subclinical infection, or
by cross-reactivity of malaria antibodies to a certain extent.
There are several hypotheses to explain these unexpected results:
First, the patients improved after the treatment and subjectively did not notice remaining minor
symptoms at the end of treatment. All these symptoms were generally mild, and the patients did
not seek medical help. It could be possible that the symptoms did not really disappear but persisted
at a level below immediate perception. This would mean that sequelae persist even more than a
decade after treatment and include headaches, pruritus, sleeping disorders, and rare neurological
deficits in the absence of persisting parasites. The description of the signs and symptoms described in
children [22,23] and case series of adults [10] strengthens the hypothesis of persistence of sequelae.
Secondly, after an initial cure, some patients could have had a relapse or a reinfection with HAT
with an oligosymptomatic presentation and trypanosomes below the detection level in the blood. Even
if HAT infections are rare events, mainly in the last decade [25], the study design does not allow the
exclusion of such reinfection or relapse.
The third hypothesis could be that a few parasites have survived (hiding in other compartments
than the blood) and may have caused a persisting oligosymptomatic low-level infection. Treatment with
melarsoprol, which reaches nearly all compartments of the body, killed the trypanosomes, but neither
pentamidine nor pafuramidine, used against first stage HAT, can penetrate the blood brain barrier
and may not have reached all body compartments. Tanowitz described replicating trypanosomes
in adipose tissue interacting with adipocytes [26]. Since most drugs used for the treatment of HAT
are hydrophilic, their efficacy could be limited in a lipophilic environment, and adipose tissue could
represent a safe site for trypanosomes to hide [26]. It has been described that the skin or the CSF
could also represent an anatomic reservoir of trypanosomes [21,27]. In addition, the persistence of
trypanosomes in the blood below the detection level cannot be ruled out.
Of interest are the results of a study where untreated HAT patients were compared to formerly
treated HAT patients [10]. Eleven HAT patients refused treatment, survived, and were evaluated
2–9 years later. Parasites were detected in only one out of 11 patients in the blood (by microscopy and
PCR), and HAT specific antibody titres had decreased in only seven out of 10 patients. The study
suggests that oligo-or asymptomatic HAT infections may show spontaneous cure over time or persist
as low level infection without passage to the CNS [10]. The control group included 18 first stage and
21 second stage HAT patients treated 15 years prior. No parasites could be detected in the blood of
any patients, neither by PCR nor by microscopy after mini anion exchange centrifugation technique.
A combination of a positive immune trypanolysis test [28] with a negative CATT test was found in
61.5% [10]. In 58% of the treated and in 68% of the untreated patients, non-specific symptoms such as
fever and headaches were observed, showing that such symptoms may persist for a long time [10].
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The findings lead to the hypothesis that a few surviving trypanosomes in certain compartments
could partially be controlled by the immune system, leading to minor persisting symptoms without,
however, the development of apparent clinical signs of a relapse of the disease. The persistent survival
of trypanosomes could be a source of transmission [10,11] and could explain the reactivity of the
serum in the Trypanosoma IFA in our study. The negative CATT results could possibly be explained
by either a lower sensitivity than the IFA, by the occurrence of trypanosome strains that lack or do
not express the LiTat 1.3 gene that has been described for some endemic areas in Nigeria [17], or
by the rapid decline of CATT reactivity in treated HAT patients within a few years [29] while other
serological tests are still positive. On the other hand, the negative CATT results could also mean
that anti-trypanosomal antibodies are no longer present and the positive IFA results are caused by
cross-reacting malaria antibodies.
A review of the natural progression of HAT concludes that, in rare cases, an oligosymptomatic
chronic carrier stage exists, but duration beyond six to seven years is exceptional [30]. It is also worth
paying attention to the broad spectrum of clinical presentations of T.b. gambiense HAT, ranging from a
chronic oligosymptomatic form to the frequently observed, usually fatal chronic disease in endemic
populations to the acute clinical presentation in non-endemic populations [31].
The presented results would be compatible with such a hypothesis, and the presence of antibody
titres even 14–15 years after the end of treatment supports this hypothesis, although it needs to be
confirmed by more robust data. The study demonstrates a surprisingly high percentage of HAT
patients still suffering from symptoms even more than 10 years after treatment. The study was not
designed to specify if re-infections, relapses, or parasites surviving in not yet well described body
compartments cause the signs and symptoms or if the patients have sequelae without any surviving
trypanosomes. These questions should be addressed in further studies.
5. Limitations
The limitations of this study are the subjective character of the symptoms, the difficulties
associated with properly assessing third party history, and the relatively low number of patients.
Another limitation of the study is that no Trypanosoma real time PCR and no Trypanosoma and malaria
serology was performed for treated asymptomatic patients or control group participants. These data
could not be collected due to the study design and the unexpected outcome of the first phase of the
study. Finally, cross-reactivity of malaria antibodies against T. brucei antigens or vice versa cannot be
ruled out.
6. Conclusions
We demonstrated HAT-related signs and symptoms more than 10 years after treatment for the first
time in first stage HAT patients without detectable levels of parasites. In first stage HAT patients, the
prevalence of all signs and symptoms decreased compared to before treatment, but were still higher
than at the end of treatment and in the control group. In second stage HAT patients, all HAT specific
findings had continuously decreased to the point where they were in the range of the healthy control
group. Persistence of symptoms without detectable levels of parasites in the blood could suggest either
parasitaemia below the detection level or the persistence of parasites in some other body compartments.
Further studies, including skin or tissue biopsies for detection of trypanosomes by PCR and serologic
testing before treatment as well as ten years later, could indicate if there is a reservoir, which could be
relevant for subclinical forms and transmission.
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